Gilead Sciences (GILD) Cash from Operations (2009 - 2026)

Gilead Sciences has reported Cash from Operations for 18 years, with the latest figure at 2544000000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 44.79% year-over-year to 2544000000.0; the trailing twelve-month figure through Mar 2026 stood at 10806000000.0 (up 4.24% YoY), and the FY2025 full-year result was 10019000000.0, down 7.47% from the prior year.
• Cash from Operations for Q1 2026 stood at 2544000000.0, down from 3327000000.0 in the prior quarter.
• The five-year high for Cash from Operations was 4309000000.0 in Q3 2024, with the low at 827000000.0 in Q2 2025.
• Historically, Cash from Operations has averaged 2380529411.76 across 5 years, with a median of 2219000000.0 in 2024.
• The largest YoY upside for Cash from Operations was 145.53% in 2024 against a maximum downside of 43.33% in 2024.
• Gilead Sciences' Cash from Operations stood at 2567000000.0 in 2022, then retreated by 15.5% to 2169000000.0 in 2023, then surged by 37.16% to 2975000000.0 in 2024, then advanced by 11.83% to 3327000000.0 in 2025, then slipped by 23.53% to 2544000000.0 in 2026.
• The last three Cash from Operations figures came in at 2544000000.0 (Q1 2026), 3327000000.0 (Q4 2025), and 4108000000.0 (Q3 2025), per Business Quant data.